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Glycosphingolipids (GSLs) are amphipathic molecules
with a polar glycan chain as a head group and a hydropho-
bic sphingosine-containing ceramide tail, which is typically
embedded in the outer leaflet of the plasma membrane (1).
GSLs are no longer thought to be mere physical compo-
nents of the membrane. They often cluster in “glycosignal-
ing domains” (GSDs; reference 2), sometimes along with
 
other sphingolipids, glycosylphosphatidylinositol (GPI)-
 
anchored proteins, and cholesterol, forming “lipid rafts” (3).
These microdomains are thought to regulate signal trans-
duction via cis interactions with signal transducer mole-
 
cules. A GSL called G
 
d3
 
 has recently been shown to be in-
volved in Fas-mediated apoptosis in hematopoietic cells,
causing the loss of mitochondrial potential and the release
of apoptotic factors (for reviews, see references 4 and 5). In
this issue, Malisan et al. (6) show that a naturally occurring
modification of G
 
d3
 
 (O-acetylation) can reverse its apop-
totic effects, suggesting a way for cells to avoid the fate of
G
 
d3
 
-induced apoptosis. To understand this interesting
story better, it is first necessary to review some general in-
formation about G
 
d3
 
 and O-acetylation.
 
Structure, Biosynthesis, and Tissue Distribution of G
 
D
 

 
.
 
Gangliosides are GSLs with one or more sialic acid (Sia)
residues. G
 
d3
 
 is a ganglioside with two Sias linked to a lac-
tosylceramide core common to many GSLs (see Fig. 1). Sia
is a generic name for members of a family of 9-carbon sug-
ars typically found at the termini of glycan chains on verte-
brate glycoproteins and glycolipids. Many endogenous or
exogenous receptors recognize Sias, mediating or modulat-
ing processes such as cell adhesion, differentiation, signal
transduction, pathogen invasion, or toxin action (for a re-
view, see reference 7). The biosynthesis of G
 
d3
 
 is tradi-
tionally thought to occur in the ER-Golgi pathway, by the
sequential addition to ceramide of a glucose, a galactose
and two Sia residues, each step being catalyzed by distinct
glycosyltransferases (see Fig. 1). The last three of these en-
zymes have their active sites oriented toward the lumen of
Golgi compartments. Such newly synthesized gangliosides
are delivered to the outer leaflet of the plasma membrane
and eventually turned over via endocytosis and lysosomal
degradation (1; see Fig. 1).
G
 
d3
 
 is expressed at high levels in the embryonic brain,
with marked decreases during postnatal development (8).
In normal adult humans, G
 
d3
 
 is only detectable in a few
tissue types (9), and on some T lymphocytes (10). In con-
trast, G
 
d3
 
 expression is highly elevated in melanomas, neu-
roblastomas, small cell carcinomas, and certain leukemias
(11, 12).
 
Modified Forms of G
 
D
 

 
.
 
The biological specificity of
Sias can be modulated by substitutions or modifications at
the 1, 4, 5, 7, 8, or 9 positions (7). O-acetyl esters are most
commonly found at the 9-carbon position. Such ester
groups can first be added at the 7-position and then slowly
migrate to the 9-position under physiological conditions
(7). The outermost Sia residue of G
 
d3
 
 can be 9(7)-O-
acetylated to a varying extent in various cell types. 9-O-
Acetyl-G
 
d3
 
 (9AcG
 
d3
 
) was first discovered as a surface
marker for germinal cells of the central nervous system
(13), and then structurally characterized from human mela-
noma cells (11). Interestingly, the distribution of G
 
d3
 
 and
9AcG
 
d3
 
 is not identical in some regions of the developing
 
nervous system (13–15). Elimination of 9AcG
 
d3
 
 expression
in the retina and adrenals of transgenic mice expressing an
Influenza C Sia-specific 9-O-acetylesterase gave variable
abnormalities in development (16). While many biological
roles for 9AcG
 
d3
 
 have been proposed, the evidence is indi-
rect, consisting of the effects of the viral 9-O-acetylesterase
(16, 17), or of anti-9AcG
 
d3
 
 antibodies (18, 19).
 
Postnatally, 9AcG
 
d3
 
 expression becomes restricted to the
retina and cerebellum, and the only nonneural expression
known is in the adrenal medulla, kidney glomeruli in rats,
and some human lymphoid cell types (9, 10). High expres-
sion of 9AcG
 
d3
 
 is also seen in human basal cell carcinomas
(20), and in melanomas from many species (21). The less
 
common 7-
 
O
 
-Acetyl-G
 
d3
 
 has been identified in hamster
melanomas, and in human T cell lymphocytes (22, 23). In
T lymphocytes, AcG
 
d3
 
 species appear to be the epitopes for
anti-CD60 antibodies (10), although a similar terminal
structure on glycoprotein glycans also contributes (24). An-
tibodies against G
 
d3
 
 and AcG
 
d3
 
 have been used in mela-
noma immunotherapy, so far with limited success (25–28).
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G
 
D
 

 
-induced Apoptosis.
 
G
 
d3
 
 synthesis is induced during
Fas (APO-1/CD95)-mediated apoptosis, and is then
thought to mediate the apoptotic effect by accumulating in
mitochondria (an unconventional subcellular location for a
ganglioside; reference 29). These phenomena are inhibited
by blocking G
 
d3
 
 synthase expression, indicating that de
novo synthesis of G
 
d3
 
 is required (30). In an apparently re-
lated process, apoptotic signaling is thought to occur
through Fas-mediated activation of membrane-associated
acidic sphingomyelinase (ASM), generating free ceramides
(31, 32). It is proposed that these ceramides are converted
to G
 
d3
 
 by returning to Golgi-like compartments (see Fig.
1). A similar ASM-G
 
d3
 
 pathway has been recently impli-
cated in TNF-
 
 
 
–mediated apoptosis as well (33, 34). Inde-
pendent work from others indicates that G
 
d3
 
 can be a
component of the apoptotic response in cell types such as
neurons (35), aortic smooth muscle cells (36), and kerati-
nocytes (37). In keratinocytes, the structurally related gan-
 
glioside GT1b also has a proapoptotic effect, but unlike
G
 
d3
 
, works in a fibronectin-dependent manner, apparently
involving an integrin-linked kinase (37). In another study
involving lymphoblastoid cells, G
 
d3
 
 association with the
ezrin cytoskeleton protein was proposed to be involved in
apoptosis (38). Also, low doses of G
 
d3
 
 stimulated superox-
ide generation and MAP kinase activation in human aortic
smooth muscle cells (36).
Some of the above studies took advantage of the fact
that when pure gangliosides (which are in the form of mi-
celles in aqueous solution) are added to cells or organelles
in vitro, they can become incorporated as integral compo-
nents of the outer leaflet of their membranes (39). Addi-
tion of G
 
d3
 
 to intact cells induced apoptosis, and addition
to isolated mitochondria gave a loss of mitochondrial
transmembrane potential, along with release of apoptoge-
nic factors such as cytochrome c and caspase-9. Ganglio-
sides structurally related to G
 
d3
 
 did not exhibit these ef-
Figure 1. Subcellular compartments potentially involved in the biosynthesis, trafficking, and turnover of GD3 and AcGD3 are shown. Complexities
involving 7- versus 9-AcGD3, and the possible action of O-acetylesterases are omitted. Various pathways for GD3-induced apoptosis are indicated, espe-
cially in relation to the proposed production and translocation of GD3 to mitochondrial membranes. Some of the unresolved topological issues are em-
phasized. Topological issues regarding ASM are not shown. See text for further discussion. 
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fects in most systems (29, 30, 40). Taken together, all these
data constitute a strong case for a proapoptotic role for
G
 
d3
 
. However, the mechanisms of G
 
d3
 
 action remain
obscure, and there are puzzling topological issues (see be-
low). Also, as G
 
d3
 
 is only found in a minority of adult cell
types, this may represent a specialized subset of apoptosis
control pathways. Indeed, on initial study, G
 
d3
 
 synthase
null mice apparently did not exhibit gross developmental
pathologies, nor show any differences from wild-type con-
trols in Fas-mediated apoptotic reaction of thymocytes
(41).
 
Is 9-O-acetyl G
 
D
 

 
 an Antiapoptotic Factor?
 
If G
 
d3
 
 is ex-
pressed in some normal as well as many cancer cells, how
do they escape its apoptotic effects? Writing in this issue,
Malisan et al. (6) offer an intriguing explanation. As many
cells expressing G
 
d3
 
 also have 9AcG
 
d3
 
, the authors postu-
lated that 9-O-acetylation could rescue the cell from G
 
d3
 
-
induced apoptosis. Indeed, in striking contrast to G
 
d3
 
,
9AcG
 
d3
 
 did not induce apoptosis when added to intact
cells, nor did it affect transmembrane potential, or cause the
release of apoptotic factors when added to isolated mito-
chondria. The effects were restored when 9AcG
 
d3
 
 was
chemically de-acetylated back to G
 
d3
 
, showing that the
findings were not due to an inhibitory contaminant. De-
O-acetylation of endogenous 9AcG
 
d3
 
 in intact cells was
also achieved by transfecting cells with the viral 9-O-acetyl-
esterase mentioned above. Cells that either express G
 
d3
 
synthase endogenously or by transfection became apoptotic
when the viral esterase was also present, and this correlated
with a reduction in 9AcG
 
d3
 
. The authors conclude that by
turning part of pro-apoptotic G
 
d3
 
 into ‘harmless’ 9AcG
 
d3
 
,
9-O-acetylation acts as an effective antiapoptotic mecha-
nism. Together with the action of a putative endogenous
9-O-acetylesterase, an acetylation-deacetylation cycle is
suggested as a subtle yet elegant means of regulating the ap-
optotic potential of G
 
d3
 
. Consistent with this concept is
our recent finding that the ganglioside 9-O-acetylation ma-
chinery is directly induced by the expression of G
 
d3
 
 syn-
thase (unpublished data). However, there are many unre-
solved issues.
 
What About the G
 
D
 

 
:9AcG
 
D
 

 
 Ratio?
 
A substantial amount
of G
 
d3
 
 continues to be present alongside 9AcG
 
d3
 
 in all
the situations examined. Also, in our own work using
CHO cells (42), expression of G
 
d3
 
 synthase was accompa-
nied by 9-O-acetylation of only a minor fraction of the
G
 
d3
 
, and yet no obvious apoptosis was observed. A domi-
nant effect of 9AcG
 
d3
 
 over G
 
d3
 
 could explain such find-
ings. However, mixing experiments by Malisan et al. ap-
pear to rule this out (6). It is possible that the ratios of G
 
d3
 
and 9AcG
 
d3
 
 in whole cell extracts are misleading, and that
9AcG
 
d3
 
 is selectively enriched in a critical cellular sub-
compartment involved in mediating in proapoptotic effects
of G
 
d3
 
. This could be checked by immunoelectron mi-
croscopy using the available antibodies. However, our own
work with melanoma cells indicated a similar distribution
for G
 
d3
 
 and 9AcG
 
d3
 
 in melanoma cells, with a novel in-
tracellular distribution only for another Sia variation called
de-N-acetyl G
 
d3
 
 (9).
 
Other Unresolved Subcellular and Topological Issues.
 
How
does the newly synthesized G
 
d3
 
, which is normally found
in the ER-Golgi-plasmalemma pathway reach the mito-
chondria? Perhaps this occurs via vesicular trafficking asso-
ciated with the cytoskeleton (33, 38), or through the pro-
posed mitochondria-associated membranes bridging to
ER/Golgi elements (43). Regardless, as G
 
d3
 
 is synthesized
within the lumen of the Golgi and is then embedded in the
outer leaflet of the plasma membrane, either of the above
delivery systems would cause G
 
d3
 
 incorporation into the
inner leaflet of the outer mitochondrial membrane (see Fig.
1). In contrast, the experiments with isolated mitochondria
involve added G
 
d3
 
, which should be incorporated with its
polar glycan head-group facing outward, in the cytosol-
facing leaflet of the outer mitochondrial membrane (see
Fig. 1). It is hard to imagine that these two topologically
unique forms of G
 
d3
 
 mediate the same biological actions.
Thus, one must postulate a “flippase” for gangliosides in
the mitochondria and/or in the ER-Golgi-plasmalemma
pathway that could transfer the polar headgroup between
the two leaflets.
 
A Receptor for G
 
D
 

 
?
 
A more basic question is why G
 
d3
 
is active in this pathway, but not other gangliosides with
closely related structures, including 9AcG
 
d3
 
. This implies
the existence of a receptor that specifically recognizes the
structure of G
 
d3
 
, including the outer Sia residue that be-
comes O-acetylated in 9AcG
 
d3
 
. Perhaps this proposed re-
ceptor is the same as the putative “flippase” protein? In this
regard, it is interesting that there are studies describing
“glycolipid transfer proteins” in the cytosol (44, 45). An-
other potential candidate is Bid, a proapoptotic cytosolic
factor of the Bcl-2 family, which is cleaved by FAS-induced
caspase 8 (46). Truncated Bid associates with lipid mem-
branes, has an affinity toward acidic phospholipids, and is
thought to be involved in membrane lipid transfer to mito-
chondria (47). It is thought that Bid affects the struc-
tural state of multidomain antiapoptotic Bcl-2 proteins in
the outer membrane by changing the lipid environment in
mitochondria. Perhaps Bid or another Bid-like proapop-
totic factor could be the putative G
 
d3
 
 flippase as well? This
would fit with the earlier observation that enforced expres-
sion of Bcl-2 attenuated G
 
d3
 
-induced apoptosis. Yet an-
other possibility is that a transient de-N-acetylation of G
 
d3
 
could cause it to associate strongly with phospholipids (48).
Such complexes might then be flipped over by the previ-
ously well-known phospholipid transfer proteins.
Other Missing Pieces of the Puzzle. In addition to the
mechanism of “flipping,” the immediate downstream ef-
fectors of Gd3 that induce the mitochondrial changes need
to be elucidated. Cloning of the putative Gd3:9(7)O-acetyl
transferase(s) and esterase(s) would also help in understand-
ing the regulation of 9(7)-O-acetylation in relation to Gd3
expression in different cell types and within different sub-
cellular compartments. Finally, what about the effects of
the less common intermediate form 7AcGd3, which can-
not be deacetylated by any known O-acetylesterase? Until
a clearer picture emerges regarding all these issues, the bio-
logical significance and precise mechanisms of Gd3-induced1532 Commentary
apoptosis remains somewhat of a mystery, and O-acetyl-
ation of Gd3 remains an enigmatic modification in contin-
ued search of definitive functions.
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